| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2007.14.7371 |
| P698 | PubMed publication ID | 18487565 |
| P50 | author | Everett E Vokes | Q73567428 |
| Antonius A Miller | Q110093627 | ||
| P2093 | author name string | Mark Green | |
| Lin Gu | |||
| Xiaofei Wang | |||
| Mark A Socinski | |||
| A William Blackstock | |||
| Julian Rosenman | |||
| Gregory A Masters | |||
| Jeffrey A Bogart | |||
| Michael Munley | |||
| Arthur Sleeper | |||
| Peter Ungaro | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| chemotherapy | Q974135 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 2457-2463 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. | |
| P478 | volume | 26 |
| Q33786722 | A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer |
| Q34041735 | A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer |
| Q33847603 | A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 |
| Q37975010 | A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer |
| Q35608002 | Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer |
| Q57172945 | Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy |
| Q94491922 | Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic |
| Q36101108 | C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression |
| Q53224462 | Can Hyperpolarized Helium MRI add to radiation planning and follow-up in lung cancer? |
| Q55076075 | Can Hyperpolarized Helium MRI add to radiation planning and follow‐up in lung cancer?†. |
| Q61583102 | Cancers bronchiques non à petites cellules localement avancés : quelle radiothérapie en 2014 ? |
| Q50795251 | Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. |
| Q48707805 | Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q42584254 | Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancer. |
| Q34493493 | Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen |
| Q27027626 | Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation |
| Q36617872 | Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer |
| Q37528298 | Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival? |
| Q38549486 | Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? |
| Q43000162 | Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study |
| Q37098334 | Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer |
| Q83292295 | Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer |
| Q36143838 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer |
| Q41475564 | Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy |
| Q84879558 | Emerging developments of chemoradiotherapy in stage III NSCLC |
| Q39820035 | Esophageal cancer dose escalation using a simultaneous integrated boost technique |
| Q38337069 | Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced nonsmall cell lung cancer |
| Q47757777 | Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer |
| Q37114850 | High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study |
| Q33415544 | High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study |
| Q44070976 | Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group |
| Q39510875 | Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. |
| Q38243178 | Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important? |
| Q36609568 | Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)? |
| Q34135928 | Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer |
| Q36729045 | Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer |
| Q46049056 | Lung cancer: New biological insights and recent therapeutic advances |
| Q26827571 | Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer |
| Q35290430 | PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer |
| Q35003631 | Pemetrexed for the treatment of non-small-cell lung cancer |
| Q37516506 | Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer |
| Q33385378 | Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer |
| Q37339650 | Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer |
| Q34633068 | Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma |
| Q36368864 | Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q33897625 | Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. |
| Q36874790 | Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer |
| Q38830371 | Proton beam therapy in Japan: current and future status |
| Q35103355 | Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemi |
| Q36673860 | Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial |
| Q35971034 | Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer |
| Q84582196 | Radiotherapy for locally advanced non-small cell lung cancer |
| Q34836491 | Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer |
| Q35170255 | Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. |
| Q35584002 | Recent advances in combined modality therapy |
| Q43255216 | Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer |
| Q92016948 | Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer |
| Q49724223 | Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cance |
| Q35849774 | Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. |
| Q54935881 | Stage III non-small cell lung cancer: escalation matters, but how? |
| Q35568485 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto |
| Q38226816 | Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond |
| Q38620687 | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. |
| Q48201241 | The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk |
| Q49333936 | The evolution of proton beam therapy: Current and future status |
| Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
| Q33829279 | The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy |
| Q39839019 | The role of protons in modern and biologically-guided radiotherapy |
| Q38088273 | The use of proton-beam therapy in the treatment of non-small-cell lung cancer |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q43240680 | Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy |
| Q37423919 | Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cance |
Search more.